Supernus Pharmaceuticals, Inc. (SUPN)

NASDAQ: SUPN · USD

$41.2

+0.19 (+0.5%)· Recorded snapshot

Market cap	2.4B
Revenue (ttm)	830.4M
Net income (ttm)	-109.9M
EPS (ttm)	-$1.91
Shares out	58.1M
P/E (forward)	11.6x
Volume	951,360
Beta	0.55

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 830.4M
Net income (ttm): -109.9M
EPS (ttm): -$1.91
P/E (forward): 11.6x
Market cap: 2.4B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	होल्ड

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E11.6

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-10.5

P25 n/aP50 n/aP75 n/a

ROIC1.2

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All SUPN indicators

Market & fundamental data

Available fields

243

Groups with data

Currency

USD

Showing 243 of 243 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001356576
Company name	Supernus Pharmaceuticals, Inc.
Country	United States
Country code	US
CUSIP number	868459108
Earnings date	2026-10-29
Earnings time	amc
Employees	778
Employees change	104
Employees growth	15.43%
Enterprise value	$2.1B
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2005
In index	RUSSELL2000
Industry	Drug Manufacturers - Specialty & Generic
IPO date	2012-05-01
Is primary listing	Yes
Is SPAC	No
ISIN number	US8684591089
Last 10-K release date	2026-03-02
Last earnings date	2026-08-03
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$2.4B
Market cap category	Mid-Cap
Next earnings date	2026-10-29
Options	Yes
Price	$41.15
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	SUPN
U.S. state	Maryland
Website	https://www.supernus.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Adjusted P/E ratio	18.47x
Average P/E ratio (10Y)	65.07x
Average P/E ratio (5Y)	127.05x
Earnings yield	-4.65%
EV/EBIT	229.95x
EV/EBITDA	18.18x
EV/FCF	106.87x
EV/Sales	2.42x
FCF / EV yield	0.94%
FCF yield	0.8%
Forward EV/Sales	1.6x
Forward P/E	11.62x
Forward P/S	1.86x
Industry forward P/E	13.86x
Industry P/E	173.47x
P/B ratio	2.31x
P/FCF ratio	124.53x
P/OCF ratio	117.5x
P/S ratio	2.82x
PEG ratio	0.61x
Price / tangible book value	5.29x
Price/EBITDA ratio	21.19x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	1.05%
EBITDA margin	13.3%
FCF margin	2.26%
Gross margin	72.89%
Operating margin	1.05%
Pretax margin	-14.87%
Profit margin	-13.23%
Profit per employee	$-141,242
Revenue per employee	$1.1M
ROA	0.39%
ROA (5Y)	1.88%
ROCE	0.81%
ROE	-10.49%
ROE (5Y)	3.6%
ROIC	1.22%
ROIC (5Y)	4.69%
SBC / revenue	4.17%
Tax / revenue	-1.64%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	0
FCF growth	-89.89%
FCF growth 3Y	-35.83%
FCF growth 5Y	-30.69%
Gross profit growth	40.44%
Gross profit growth (Q)	23.25%
Gross profit growth 3Y	3.84%
Gross profit growth 5Y	4.27%
Net income growth years	0
OCF growth	-89.36%
OCF growth 10Y	-5.6%
OCF growth 3Y	-34.75%
OCF growth 5Y	-30.18%
Operating income growth	-83.06%
Operating income growth 3Y	-20.88%
Operating income growth 5Y	-43.3%
Revenue growth	24.85%
Revenue growth (Q)	32.4%
Revenue growth (QoQ)	5.47%
Revenue growth 10Y	16.59%
Revenue growth 3Y	9.41%
Revenue growth 5Y	7.78%
Revenue growth quarters	4
Revenue growth years	2

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-1.1M
Depreciation and amortization	$101.7M
EBIT	$8.7M
EBITDA	$110.4M
EPS	$-1.91
FCF per share	$0.32
Financing cash flow	$31.5M
Free cash flow	$18.8M
Free cash flow minus SBC	$-15.8M
Gross profit	$605.3M
Income taxes	$-13.6M
Investing cash flow	$-14.7M
Net cash flow	$36.7M
Net income	$-109.9M
Operating cash flow minus SBC	$-14.7M
Operating income	$8.7M
Revenue	$830.4M
Stock-based compensation	$34.6M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	5.41
Book value per share	$17.73
Debt / EBITDA	0.32
Debt / equity	0.04
Debt / FCF	2.14
Goodwill	$119.4M
Interest coverage	3.77
Long-term assets	$704.6M
Long-term liabilities	$49.5M
Net cash (debt)	$331.9M
Net cash / market cap	14.19%
Net cash growth	-32.38%
Net debt / EBITDA	-3.01
Net debt / equity	-0.32
Net debt / FCF	-17.67
Piotroski F-Score	5
Property, plant and equipment	$35.6M
Shareholders' equity	$1B
Tangible book value	$442.3M
Tangible book value per share	$7.60
Total assets	$1.4B
Total cash	$372.1M
Total debt	$40.2M
Total liabilities	$396.9M
WACC	7.25%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.59
Current assets	$723.5M
Current liabilities	$347.4M
Current ratio	2.08
Inventory turnover	3.52
Net working capital	$14.8M
Quick ratio	1.68
Working capital	$376.1M
Working capital turnover	2

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-1.67%
Dividend yield	0%
Shareholder yield	-1.67%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	98.92%
10Y return CAGR	7.12%
10Y total return	98.92%
150-day SMA	$46.16
1D price change	0.46%
1M price change	-5.11%
1M total return	-5.11%
1W price change	-1.82%
1W total return	-1.82%
1Y price change	-23.22%
1Y return CAGR	-23.23%
1Y total return	-23.22%
20-day SMA	$41.39
200-day SMA	$47.38
3M price change	-13.84%
3M total return	-13.84%
3Y price change	71.82%
3Y return CAGR	19.77%
3Y total return	71.82%
50-day SMA	$42.73
50-day SMA vs 200-day SMA	50under200
52-week high	$59.68
52-week high date	2026-02-25
52-week low	$37.54
52-week low date	2026-10-16
5Y price change	37.88%
5Y return CAGR	6.64%
5Y total return	37.88%
6M price change	-18.16%
6M total return	-18.16%
All-time high	$61.25
All-time high date	2018-06-29
All-time low	$4.30
All-time low date	2012-06-05
Average true range (ATR)	$1.61
Average volume	954.3K
Beta (1Y)	0.96
Beta (2Y)	0.68
Beta (5Y)	0.55
Change from 52-week high	-31.05%
Change from 52-week low	9.62%
Change from all-time high	-33.91%
Change from all-time low	841.4%
Change from open	2.19%
Day's gap	-1.68%
Dollar volume	$39.1M
High price	$41.15
Low price	$39.76
Monthly RSI	48.06
Open price	$40.27
Position in 52-week range	100%
Premarket change	-0.02%
Premarket close	$40.96
Premarket price	$40.95
Premarket volume	904
Previous close	$40.96
Price vs 150-day SMA	-12.31%
Price vs 20-day SMA	-2.19%
Price vs 200-day SMA	-14.56%
Price vs 50-day SMA	-5.27%
Relative volume	1
RSI	43.7
Sharpe ratio	-0.64
Sharpe ratio (3Y)	0.56
Sharpe ratio (5Y)	0.24
Sortino ratio	-0.7
Sortino ratio (3Y)	0.99
Sortino ratio (5Y)	0.5
Volume	951.4K
Weekly RSI	40.3
YTD price change	-18.55%
YTD total return	-18.55%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	51.7M
Float percentage	89.02%
Shares change (QoQ)	0.73%
Shares change (YoY)	1.67%
Shares held by insiders	4.33%
Shares held by institutions	97.92%
Shares outstanding	58.1M
Short % of float	7.81%
Short % of shares	6.96%
Short ratio	7.9 days

Deeper analysis on SUPN

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this SUPN report

Is a complete SUPN research report available?

No complete published report is available for Supernus Pharmaceuticals, Inc. (SUPN) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Supernus Pharmaceuticals, Inc. (SUPN)

Price

Financial snapshot

Fair-value bridge

Latest news · SUPN

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All SUPN indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on SUPN

Frequently asked questions